XNK02 / XNK Therap - LARVOL DELTA

XNK Therapeutics enters into research collaboration with Karolinska University Hospital in acute myeloid leukemia (AML) (PRNewswire) - "XNK Therapeutics AB...today announced that the company has entered into a research collaboration with the Karolinska University Hospital, Sweden, to evaluate the suitability of the company's autologous natural killer (NK) cell therapy candidate XNK02 as a novel therapy for treatment of acute myeloid leukemia (AML)...In collaboration with Karolinska University Hospital, XNK will perform a large-scale bioreactor culture study of AML patients' immune cells....The study aims to further investigate the expansion procedure (NK cell growth) and to study the properties of the expanded NK cells with respect to their ability to kill the patient's own tumor cells ex vivo."

Licensing / partnership • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

XNK Therapeutics to present two posters at the NK2023 conference in Oslo in September (PRNewswire) - "XNK Therapeutics AB today announced that two posters, regarding bladder cancer and acute myeloid leukemia (AML) respectively, will be presented at the 20th Meeting of the Society for Natural Immunity (NK2023) in Oslo, Norway, in September...The data have been generated in collaboration with XNK's external partners, Anders Ullén and Fernanda Costa Svedman at the Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden, for the bladder cancer abstract, and Abhishek Maiti and Naval Daver at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA, for the AML abstract."

Clinical data • Acute Myelogenous Leukemia • Bladder Cancer • Genito-urinary Cancer • Hematological Malignancies • Leukemia • Oncology • Solid Tumor • Urothelial Cancer

XNK Therapeutics enters into agreement with US-based biotechnology company (PRNewswire) - "XNK Therapeutics AB...today announced that the company has entered into an agreement with a US biotechnology company. Under the agreement the parties will perform preclinical evaluation of XNK's autologous NK cell therapy candidate XNK02 in combination with a drug candidate currently in clinical development by the US company. The combination will initially be tested against acute myeloid leukemia (AML)....The collaboration supplements XNK's current collaborations in the field of AML with the University of Texas MD Anderson Cancer Center."

Licensing / partnership • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

XNK Therapeutics to present two abstracts at the Society for Immunotherapy of Cancer's meeting in San Diego in November (PRNewswire) - "XNK Therapeutics...announced that the abstracts Harnessing the potential of autologous NK cells for immunotherapy of patients with advanced bladder cancer and Feeder-Free Expansion of Autologous Cytotoxic NK Cells for Acute Myeloid Leukemia Treatment will be presented at the 38th Meeting of the Society for Immunotherapy of Cancer (SITC) in San Diego in November....The data have been generated in collaboration with XNK's external partners, Anders Ullén and Fernanda Costa Svedman at the Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden, for the bladder cancer abstract, and Abhishek Maiti and Naval Daver at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA, for the AML abstract."

Preclinical • Acute Myelogenous Leukemia • Bladder Cancer • Genito-urinary Cancer • Hematological Malignancies • Leukemia • Oncology • Solid Tumor